isoniazid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1497	54-85-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: isoniazid 4-Pyridinecarboxylic hydrazide armazid isoniazide isonicotinohydrazide	Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Molecular weight: 137.14 Formula: C6H7N3O CLOGP: -0.67 LIPINSKI: 0 HAC: 4 HDO: 2 TPSA: 68.01 ALOGS: -0.59 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

isoniazid
4-Pyridinecarboxylic hydrazide
armazid
isoniazide
isonicotinohydrazide

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

Molecular weight: 137.14
Formula: C6H7N3O
CLOGP: -0.67
LIPINSKI: 0
HAC: 4
HDO: 2
TPSA: 68.01
ALOGS: -0.59
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
0.30	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	153 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	7 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	72.92 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	80 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.82 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 29, 1952	FDA	SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	595.92	13.51	273	18536	29275	46637978
Drug-induced liver injury	454.35	13.51	216	18593	25152	46642101
Tuberculosis	400.57	13.51	152	18657	10113	46657140
Paradoxical drug reaction	380.11	13.51	103	18706	2273	46664980
Acute hepatic failure	337.82	13.51	149	18660	14572	46652681
Hepatotoxicity	241.58	13.51	141	18668	24868	46642385
Drug resistance	236.96	13.51	123	18686	17245	46650008
Hepatitis	235.50	13.51	152	18657	32063	46635190
Pulmonary tuberculosis	228.54	13.51	82	18727	4649	46662604
Tuberculoma of central nervous system	191.85	13.51	40	18769	263	46666990
Jaundice	188.68	13.51	127	18682	28718	46638535
Disseminated tuberculosis	164.83	13.51	56	18753	2696	46664557
Immune reconstitution inflammatory syndrome associated tuberculosis	159.73	13.51	36	18773	355	46666898
Hepatic encephalopathy	150.28	13.51	76	18733	10081	46657172
Immune reconstitution inflammatory syndrome	144.47	13.51	62	18747	5663	46661590
Drug interaction	129.14	13.51	265	18544	202829	46464424
Pyrexia	126.24	13.51	366	18443	348436	46318817
Liver injury	113.17	13.51	74	18735	15927	46651326
Transaminases increased	92.68	13.51	82	18727	27679	46639574
Hepatic failure	90.82	13.51	88	18721	33328	46633925
Cerebellar ataxia	89.64	13.51	27	18782	877	46666376
Hepatocellular injury	86.41	13.51	81	18728	29441	46637812
Hepatic function abnormal	84.94	13.51	86	18723	34335	46632918
Lymph node tuberculosis	84.68	13.51	25	18784	757	46666496
Eosinophilia	83.27	13.51	66	18743	19151	46648102
Alanine aminotransferase increased	78.05	13.51	133	18676	88318	46578935
Lymphadenopathy	77.80	13.51	81	18728	33407	46633846
Aspartate aminotransferase increased	72.97	13.51	121	18688	78579	46588674
Hepatitis fulminant	70.21	13.51	32	18777	3370	46663883
Tuberculin test positive	64.35	13.51	29	18780	2975	46664278
Exposure during pregnancy	61.41	13.51	135	18674	108077	46559176
Encephalopathy	60.31	13.51	71	18738	33518	46633735
Tuberculosis gastrointestinal	59.32	13.51	16	18793	346	46666907
Pneumocystis jirovecii pneumonia	58.94	13.51	49	18760	15199	46652054
Loss of employment	57.76	13.51	21	18788	1235	46666018
Peritoneal tuberculosis	56.92	13.51	17	18792	536	46666717
Mycobacterium tuberculosis complex test positive	56.62	13.51	22	18787	1556	46665697
Meningitis tuberculous	56.15	13.51	17	18792	562	46666691
Tuberculosis of central nervous system	54.05	13.51	15	18794	362	46666891
Latent tuberculosis	52	13.51	22	18787	1938	46665315
Pain	47.92	13.51	74	18735	476874	46190379
Liver transplant	47.57	13.51	22	18787	2395	46664858
Generalised tonic-clonic seizure	46.49	13.51	56	18753	27066	46640187
Liver disorder	43.90	13.51	64	18745	37182	46630071
Fatigue	43.60	13.51	115	18694	608582	46058671
Glomerulonephritis minimal lesion	43.55	13.51	11	18798	182	46667071
Rash maculo-papular	38.97	13.51	52	18757	27822	46639431
Hepatitis toxic	37.34	13.51	20	18789	2980	46664273
Fall	37.04	13.51	47	18762	329050	46338203
Product dose omission issue	35.18	13.51	12	18797	168508	46498745
Coagulopathy	33.02	13.51	39	18770	18460	46648793
Focal dyscognitive seizures	32.83	13.51	18	18791	2810	46664443
Hepatic necrosis	32.67	13.51	23	18786	5578	46661675
Hepatosplenomegaly	32.64	13.51	17	18792	2393	46664860
Serpiginous choroiditis	32.59	13.51	6	18803	18	46667235
Bovine tuberculosis	32.15	13.51	7	18802	58	46667195
Hepatic haematoma	30.73	13.51	10	18799	420	46666833
Tuberculous pleurisy	30.42	13.51	10	18799	434	46666819
Choroiditis	30.39	13.51	8	18801	157	46667096
Myocarditis	30.17	13.51	25	18784	7714	46659539
Hypertransaminasaemia	29.32	13.51	18	18791	3470	46663783
Serotonin syndrome	29.09	13.51	42	18767	24178	46643075
Face oedema	28.74	13.51	37	18772	19116	46648137
C-reactive protein increased	26.55	13.51	67	18742	58523	46608730
Multiple-drug resistance	26.17	13.51	15	18794	2550	46664703
Hemianopia heteronymous	26.11	13.51	6	18803	65	46667188
Immune system disorder	25.45	13.51	23	18786	7972	46659281
Jarisch-Herxheimer reaction	25.35	13.51	8	18801	304	46666949
Drug level decreased	24.95	13.51	20	18789	5892	46661361
Neurotoxicity	24.62	13.51	29	18780	13688	46653565
Aspergillus infection	24.28	13.51	21	18788	6869	46660384
Liver function test abnormal	24.10	13.51	56	18753	46431	46620822
Lupus-like syndrome	23.86	13.51	22	18787	7822	46659431
Ocular icterus	23.71	13.51	16	18793	3624	46663629
Microcytic anaemia	23.55	13.51	15	18794	3083	46664170
Hepatic enzyme increased	23.09	13.51	79	18730	81708	46585545
Interstitial lung disease	22.70	13.51	60	18749	53889	46613364
Trichophytosis	22.30	13.51	5	18804	48	46667205
Death	21.99	13.51	66	18743	335482	46331771
Anxiety	21.48	13.51	25	18784	181932	46485321
Pericarditis tuberculous	21.04	13.51	4	18805	15	46667238
Gamma-glutamyltransferase increased	20.76	13.51	42	18767	31698	46635555
Hepatitis B core antibody positive	20.57	13.51	6	18803	174	46667079
Pleural effusion	19.91	13.51	76	18733	82876	46584377
Hyperinsulinaemia	19.90	13.51	5	18804	81	46667172
Feeling abnormal	19.81	13.51	13	18796	125047	46542206
Blood bilirubin increased	19.75	13.51	43	18766	34141	46633112
Central venous pressure increased	19.62	13.51	5	18804	86	46667167
Liver transplant rejection	19.43	13.51	10	18799	1373	46665880
Diarrhoea	19.43	13.51	139	18670	559463	46107790
Nephrotic syndrome	19.40	13.51	16	18793	4905	46662348
Muscle spasms	19.23	13.51	13	18796	123100	46544153
Rash morbilliform	19.06	13.51	13	18796	2996	46664257
Vomiting	18.89	13.51	271	18538	452523	46214730
Blood beta-D-glucan increased	18.65	13.51	6	18803	243	46667010
Granuloma	18.53	13.51	14	18795	3784	46663469
Lymphadenitis	18.29	13.51	12	18797	2593	46664660
Joint tuberculosis	18.28	13.51	5	18804	114	46667139
Substance-induced psychotic disorder	18.24	13.51	10	18799	1560	46665693
Cerebrovascular accident	18.15	13.51	9	18800	101030	46566223
Mycobacterial infection	17.87	13.51	10	18799	1623	46665630
Pneumonia lipoid	17.59	13.51	5	18804	132	46667121
Stillbirth	17.44	13.51	17	18792	6474	46660779
Hepatic steatosis	17.15	13.51	33	18776	24009	46643244
Optic neuropathy	16.99	13.51	10	18799	1786	46665467
Cytomegalovirus infection	16.93	13.51	28	18781	18116	46649137
Immunosuppressant drug level decreased	16.85	13.51	8	18801	924	46666329
Toxic optic neuropathy	16.82	13.51	5	18804	155	46667098
Acute respiratory distress syndrome	16.77	13.51	31	18778	21891	46645362
Drug level increased	16.59	13.51	28	18781	18413	46648840
Chromaturia	16.53	13.51	25	18784	14994	46652259
Pathogen resistance	16.53	13.51	16	18793	6044	46661209
Constipation	16.48	13.51	28	18781	174069	46493184
Depression	16.43	13.51	27	18782	170077	46497176
Hepatic cyst	15.74	13.51	14	18795	4752	46662501
Mycobacterium avium complex infection	15.74	13.51	11	18798	2637	46664616
Cholestatic liver injury	15.59	13.51	10	18799	2080	46665173
Bilirubin conjugated increased	15.55	13.51	11	18798	2687	46664566
Organising pneumonia	15.40	13.51	14	18795	4888	46662365
Drug hypersensitivity	15.22	13.51	49	18760	243776	46423477
Transplant rejection	15.12	13.51	19	18790	9577	46657676
Liver palpable	14.92	13.51	3	18806	16	46667237
Optic neuritis	14.84	13.51	16	18793	6855	46660398
Granulomatous dermatitis	14.24	13.51	4	18805	101	46667152
Completed suicide	14.24	13.51	23	18786	145897	46521356
Sinusitis	14.08	13.51	19	18790	129749	46537504
Contusion	13.98	13.51	9	18800	87478	46579775
Hyperuricaemia	13.90	13.51	13	18796	4704	46662549
Toxoplasmosis	13.81	13.51	8	18801	1386	46665867
Antipsychotic drug level above therapeutic	13.79	13.51	7	18802	934	46666319
Encephalitis	13.79	13.51	16	18793	7432	46659821
Paraparesis	13.78	13.51	9	18800	1930	46665323
Memory impairment	13.72	13.51	7	18802	77330	46589923
Status epilepticus	13.62	13.51	22	18787	13957	46653296
Mycoplasma genitalium infection	13.56	13.51	3	18806	27	46667226
Central nervous system immune reconstitution inflammatory response	13.56	13.51	3	18806	27	46667226

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	787.91	13.79	205	18217	2457	29931599
Tuberculosis	461.23	13.79	177	18245	7900	29926156
Drug-induced liver injury	406.66	13.79	217	18205	21057	29912999
Drug reaction with eosinophilia and systemic symptoms	388.70	13.79	233	18189	28255	29905801
Immune reconstitution inflammatory syndrome	365.98	13.79	155	18267	8946	29925110
Hepatotoxicity	326.88	13.79	178	18244	17967	29916089
Jaundice	293.21	13.79	205	18217	32281	29901775
Pulmonary tuberculosis	275.60	13.79	106	18316	4751	29929305
Drug resistance	219.70	13.79	143	18279	19990	29914066
Hepatitis	187.52	13.79	135	18287	22221	29911835
Immune reconstitution inflammatory syndrome associated tuberculosis	181.85	13.79	44	18378	381	29933675
Tuberculoma of central nervous system	176.05	13.79	40	18382	255	29933801
Disseminated tuberculosis	145.18	13.79	53	18369	2049	29932007
Meningitis tuberculous	117.64	13.79	33	18389	532	29933524
Pyrexia	92.22	13.79	391	18031	294098	29639958
Immune system disorder	91.18	13.79	47	18375	4230	29929826
Acute hepatic failure	89.14	13.79	67	18355	11760	29922296
Serpiginous choroiditis	75.83	13.79	16	18406	68	29933988
Drug interaction	74.34	13.79	280	18142	199288	29734768
Latent tuberculosis	69.90	13.79	25	18397	910	29933146
Alanine aminotransferase increased	69.59	13.79	146	18276	74130	29859926
Lymph node tuberculosis	68.95	13.79	21	18401	457	29933599
Death	68.00	13.79	72	18350	357211	29576845
Optic neuritis	64.53	13.79	34	18388	3200	29930856
Hepatic function abnormal	64.17	13.79	102	18320	41843	29892213
Tuberculosis of central nervous system	63.69	13.79	16	18406	164	29933892
Granuloma	61.95	13.79	30	18392	2362	29931694
Hepatitis toxic	59.49	13.79	28	18394	2069	29931987
Hepatic failure	59.41	13.79	88	18334	33955	29900101
Lymphadenopathy	57.64	13.79	73	18349	24303	29909753
Liver function test abnormal	56.90	13.79	82	18340	30868	29903188
Fall	55.96	13.79	21	18401	181851	29752205
Hepatic enzyme increased	54.77	13.79	84	18338	33410	29900646
Bone tuberculosis	54.18	13.79	16	18406	312	29933744
Hepatitis fulminant	50.45	13.79	31	18391	3910	29930146
Tubulointerstitial nephritis	49.47	13.79	58	18364	17833	29916223
Aspartate aminotransferase increased	48.50	13.79	115	18307	63307	29870749
Hydrocephalus	48.39	13.79	31	18391	4206	29929850
Tuberculous pleurisy	47.70	13.79	15	18407	364	29933692
Skin disorder	46.88	13.79	46	18376	11562	29922494
Tuberculosis gastrointestinal	41.75	13.79	12	18410	212	29933844
Transaminases increased	41.43	13.79	61	18361	23396	29910660
Demodicidosis	41.33	13.79	11	18411	144	29933912
Optic neuropathy	40.66	13.79	20	18402	1629	29932427
Tuberculosis of eye	39.37	13.79	8	18414	27	29934029
Peritoneal tuberculosis	38.70	13.79	13	18409	391	29933665
Mycobacterium tuberculosis complex test positive	37.37	13.79	16	18406	945	29933111
Tuberculin test positive	36.90	13.79	16	18406	975	29933081
Granulomatous liver disease	35.84	13.79	13	18409	493	29933563
Drug level decreased	35.33	13.79	29	18393	5776	29928280
Hepatocellular injury	34.95	13.79	59	18363	25412	29908644
Bovine tuberculosis	33.26	13.79	9	18413	126	29933930
Type III immune complex mediated reaction	31.83	13.79	10	18412	242	29933814
Drug eruption	31.56	13.79	46	18376	17480	29916576
Eosinophilia	31.30	13.79	52	18370	22108	29911948
Optic atrophy	30.44	13.79	13	18409	763	29933293
Disseminated Bacillus Calmette-Guerin infection	30.04	13.79	8	18414	105	29933951
Liver disorder	29.64	13.79	60	18362	29662	29904394
Toxic epidermal necrolysis	29.32	13.79	45	18377	17895	29916161
Colour blindness	28.60	13.79	9	18413	219	29933837
Myocardial infarction	27.71	13.79	22	18400	125603	29808453
Liver injury	27.52	13.79	36	18386	12364	29921692
Blood bilirubin increased	27.51	13.79	66	18356	36570	29897486
Completed suicide	26.60	13.79	14	18408	99478	29834578
Condition aggravated	26.54	13.79	160	18262	137706	29796350
Atrial fibrillation	26.38	13.79	17	18405	108107	29825949
Splenic abscess	26.06	13.79	9	18413	295	29933761
Hyperuricaemia	25.66	13.79	27	18395	7367	29926689
Lichenoid keratosis	25.61	13.79	16	18406	2078	29931978
Extrapulmonary tuberculosis	25.36	13.79	7	18415	106	29933950
Mycobacterium fortuitum infection	25.33	13.79	8	18414	197	29933859
Diarrhoea	25.15	13.79	113	18309	333990	29600066
Cholestasis	24.44	13.79	50	18372	24900	29909156
Pain	24.42	13.79	43	18379	172598	29761458
Product dose omission issue	24.34	13.79	13	18409	91618	29842438
Papilloma	24.33	13.79	7	18415	124	29933932
Hepatic encephalopathy	23.76	13.79	36	18386	14156	29919900
Bilirubin conjugated increased	23.08	13.79	18	18404	3333	29930723
Multiple-drug resistance	22.90	13.79	17	18405	2924	29931132
Oral candidiasis	22.81	13.79	31	18391	11040	29923016
Rash maculo-papular	22.64	13.79	49	18373	25369	29908687
Hypotension	22.47	13.79	57	18365	200508	29733548
Dermatitis exfoliative	22.00	13.79	25	18397	7431	29926625
Papule	21.95	13.79	17	18405	3116	29930940
Ocular toxicity	21.84	13.79	7	18415	181	29933875
Pericarditis tuberculous	21.20	13.79	6	18416	100	29933956
Diaphragmatic injury	21.12	13.79	5	18417	39	29934017
Malignant neoplasm progression	21.12	13.79	9	18413	72278	29861778
Erythrodermic psoriasis	21.08	13.79	10	18412	752	29933304
Tuberculosis of genitourinary system	20.90	13.79	5	18417	41	29934015
Hepatic necrosis	20.83	13.79	18	18404	3845	29930211
Mycobacterial infection	20.67	13.79	13	18409	1708	29932348
Transient aphasia	20.46	13.79	6	18416	114	29933942
Red man syndrome	20.24	13.79	10	18412	822	29933234
Unmasking of previously unidentified disease	20.15	13.79	9	18413	589	29933467
Central nervous system vasculitis	20.12	13.79	8	18414	391	29933665
Liver transplant rejection	20.08	13.79	14	18408	2184	29931872
Encephalopathy	20.00	13.79	54	18368	32151	29901905
Complications of transplanted kidney	19.90	13.79	18	18404	4083	29929973
Tuberculoid leprosy	19.84	13.79	5	18417	52	29934004
Chronic allograft nephropathy	19.75	13.79	11	18411	1155	29932901
Cardiac failure congestive	19.61	13.79	14	18408	84393	29849663
Mitochondrial neurogastrointestinal encephalopathy	19.57	13.79	4	18418	14	29934042
Dilatation intrahepatic duct acquired	19.50	13.79	5	18417	56	29934000
Pulmonary sequestration	19.42	13.79	5	18417	57	29933999
Thalamic infarction	19.42	13.79	9	18413	642	29933414
Tuberculosis liver	19.04	13.79	5	18417	62	29933994
Constipation	18.96	13.79	25	18397	112881	29821175
Trisomy 21	18.90	13.79	8	18414	459	29933597
Anaplastic astrocytoma	18.58	13.79	6	18416	159	29933897
Feeling abnormal	18.36	13.79	6	18416	56750	29877306
Dyspnoea	18.33	13.79	125	18297	333170	29600886
Granulomatous lymphadenitis	18.28	13.79	5	18417	73	29933983
Ototoxicity	17.92	13.79	11	18411	1385	29932671
Cryptococcosis	17.70	13.79	12	18410	1790	29932266
Cachexia	17.55	13.79	21	18401	6590	29927466
Fatigue	17.27	13.79	121	18301	320552	29613504
Liver transplant	17.06	13.79	14	18408	2788	29931268
Psoas abscess	16.98	13.79	8	18414	592	29933464
Hemianopia heteronymous	16.59	13.79	4	18418	34	29934022
Genitourinary tract infection	16.58	13.79	5	18417	105	29933951
Coronary artery disease	16.54	13.79	5	18417	49707	29884349
Past-pointing	16.49	13.79	4	18418	35	29934021
Protrusion tongue	16.45	13.79	6	18416	231	29933825
Pneumocystis jirovecii pneumonia	16.40	13.79	34	18388	17086	29916970
Spermatozoa progressive motility abnormal	16.20	13.79	4	18418	38	29934018
Testicular mass	15.87	13.79	5	18417	122	29933934
Herpes zoster meningoencephalitis	15.78	13.79	6	18416	260	29933796
Leprosy	15.68	13.79	5	18417	127	29933929
Spermatozoa progressive motility decreased	15.43	13.79	5	18417	134	29933922
Urogenital infection bacterial	15.35	13.79	4	18418	48	29934008
Insomnia	15.32	13.79	21	18401	93315	29840741
Myxoedema coma	15.12	13.79	6	18416	292	29933764
Cell death	15.02	13.79	12	18410	2299	29931757
Vaccination failure	14.86	13.79	5	18417	151	29933905
Encephalitis	14.77	13.79	19	18403	6417	29927639
Chronic obstructive pulmonary disease	14.71	13.79	5	18417	46121	29887935
Vasculitis	14.42	13.79	21	18401	7969	29926087
Chorioretinitis	14.30	13.79	5	18417	170	29933886
Hypermetabolism	14.30	13.79	5	18417	170	29933886
Cardiac arrest	14.16	13.79	22	18400	92828	29841228
Mycobacterium abscessus infection	14.10	13.79	7	18415	581	29933475
Face oedema	13.91	13.79	25	18397	11309	29922747

Pharmacologic Action:

Source	Code	Description
ATC	J04AC01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Hydrazides
ATC	J04AC51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Hydrazides
ATC	J04AM01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM07	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
FDA EPC	N0000175483	Antimycobacterial
CHEBI has role	CHEBI:33231	antitubercular
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D000995	Antitubercular Agents
MeSH PA	D054872	Fatty Acid Synthesis Inhibitors
MeSH PA	D000960	Hypolipidemic Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Inactive tuberculosis	indication	11999007
Acute tuberculosis	indication	25629007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Tuberculosis of meninges	off-label use	58437007
Atypical mycobacterial infection	off-label use	111812000
Nutritional disorder	contraindication	2492009	DOID:374
Alcoholism	contraindication	7200002
Jaundice	contraindication	18165001
Acute hepatitis	contraindication	37871000
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Gout	contraindication	90560007	DOID:13189
Anemia due to enzyme deficiency	contraindication	111577008
Acute hepatic failure	contraindication	197270009
Disease of liver	contraindication	235856003	DOID:409
Diabetic - poor control	contraindication	268519009
Peripheral nerve disease	contraindication	302226006
Porphyria	contraindication	418470004
Diabetic peripheral neuropathy	contraindication	424736006
Slow acetylator due to N-acetyltransferase enzyme variant	contraindication	425079005
Prolonged-Severe Nausea and Vomiting	contraindication
Chronic Hepatic Disease	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.98	acidic
pKa2	3.79	Basic
pKa3	1.94	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	5.31	WOMBAT-PK
Cytochrome P450 3A5	Enzyme	P20815	CP3A5_HUMAN		IC50	4.96	WOMBAT-PK
Enoyl-[acyl-carrier-protein] reductase [NADH]	Enzyme		INHA_MYCTU	INHIBITOR			WOMBAT-PK	CHEMBL
Catalase-peroxidase	Enzyme		KATG_MYCTO				WOMBAT-PK
Dihydrofolate reductase	Enzyme		DYR_MYCTU		Ki	9	CHEMBL

External reference:

ID	Source
4017505	VUID
N0000145890	NUI
D00346	KEGG_DRUG
4017505	VANDF
C0022209	UMLSCUI
CHEBI:6030	CHEBI
NIZ	PDB_CHEM_ID
3767	PUBCHEM_CID
CHEMBL64	ChEMBL_ID
DB00951	DRUGBANK_ID
D007538	MESH_DESCRIPTOR_UI
4188	INN_ID
V83O1VOZ8L	UNII
6038	RXNORM
2955	MMSL
4929	MMSL
d00101	MMSL
002844	NDDF
387472004	SNOMEDCT_US
81335000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1655	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0440-7655	TABLET	300 mg	ORAL	ANDA	22 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1109	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0066	TABLET	100 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0071	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3056	INJECTION, SOLUTION	100 mg	INTRAMUSCULAR	ANDA	25 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	10135-584	TABLET	300 mg	ORAL	ANDA	22 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	10544-087	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	10544-121	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	10544-218	TABLET	300 mg	ORAL	ANDA	22 sections
ISONIAZID	HUMAN PRESCRIPTION DRUG LABEL	1	16590-984	TABLET	300 mg	ORAL	ANDA	13 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	21695-627	TABLET	300 mg	ORAL	ANDA	22 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	43063-463	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	46287-009	SOLUTION	50 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0370	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0370	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0410	TABLET	100 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1490	SOLUTION	50 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	51079-083	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	51655-391	TABLET	300 mg	ORAL	ANDA	10 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	52959-145	TABLET	300 mg	ORAL	ANDA	22 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2920	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	53808-1041	TABLET	300 mg	ORAL	ANDA	23 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2304	TABLET	100 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	54868-2416	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	55695-027	TABLET	100 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	55695-031	SOLUTION	50 mg	ORAL	ANDA	25 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	55695-033	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	60687-553	TABLET	300 mg	ORAL	ANDA	24 sections
Isoniazid	HUMAN PRESCRIPTION DRUG LABEL	1	61748-013	TABLET	300 mg	ORAL	ANDA	23 sections